UK Companies House feature
MERCURY PHARMA GROUP LIMITED
Profile
- Company number
- 02330913
- Status
- Active
- Incorporation
- 1988-12-23
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102 (FRS 101)
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of operations as they fall due. In assessing the ability of the Company to continue as a going concern, the directors have taken account of the loss in 2024 of £21,695, the cumulative profits of £185,600, and the Company's net current assets and net asset position of £128,225 and £1,153,996, respectively at 31 December 2024. The Company's Intermediate Holding Company, APHL has provided the Company with a letter of support indicating its intention to provide the financial support required for a period of at least 12 months from the date these financial statements are approved. The Group's forecasts and projections, taking account of reasonably possible changes in trading performance, show that the Group should be able to operate with the availability of cash and cash equivalents and intercompany arrangement. After making enquiries, considering the Company's forecasts and projections and considering the letter of support received from APHL, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the directors consider it appropriate to prepare these entity financial statements on a going concern basis.”
Subsidiaries
- Mercury Pharmaceuticals Limited · 100% held · United Kingdom · Marketing, and distribution of pharmaceutical and healthcare products
- Advanz Pharma Services (UK) Limited · 100% held · United Kingdom · Management Services
- Abcur AB · 100% held · Sweden · Marketing of pharmaceutical products
- Advanz Pharma Services (India) Private Limited · 0.01% held · India · Management Services
- Mercury Pharmaceuticals (Ireland) Limited · 100% held · Ireland · Marketing and distribution of pharmaceutical products
- Advanz Pharma Generics (UK) Limited · 100% held · United Kingdom · Marketing of pharmaceutical products
- Amdipharm UK Limited · 100% held · United Kingdom · Marketing of pharmaceutical products
- Boucher & Muir Pty Limited · 28% held · Australia · Marketing and distribution of pharmaceutical products
- Amdipharm Mercury Midco UK Limited · 100% held · United Kingdom · Marketing of pharmaceutical products
- Focus Pharmaceuticals Limited · 100% held · United Kingdom · Marketing and distribution of pharmaceutical products
- Advanz Pharma (Australia) Pty Limited · 100% held · Australia · Marketing and distribution of pharmaceutical products
- Amdipharm Limited · 100% held · Ireland · Marketing and distribution of pharmaceutical products
- Amdipharm Mercury (Hong Kong) Limited · 100% held · Hong Kong · Marketing and distribution of pharmaceutical products
- Advanz Pharma Switzerland Sarl · 100% held · Switzerland · Marketing and distribution of pharmaceutical products
- Advanz Pharma Germany GmbH · 100% held · Germany · Marketing and distribution of pharmaceutical products
- Advanz Pharma Italia S.R.L · 100% held · Italy · Marketing and distribution of pharmaceutical products
- Correvio S.A.S · 100% held · France · Marketing and distribution of pharmaceutical products
- Advanz Pharma Spain S.L.U · 100% held · Spain · Marketing and distribution of pharmaceutical products
- Advanz Pharma Belgium Sprl · 100% held · Belgium · Management services
- Correvio (Australia) Pty Ltd · 100% held · Australia · Management services
- Correvio (UK) Ltd · 100% held · United Kingdom · Management services
- Advanz Pharma Canada Inc · 100% held · Canada · Marketing and distribution of pharmaceutical products
- Advanz Pharma Specialty Medicine Switzerland GmbH · 100% held · Switzerland · Marketing and distribution of pharmaceutical products
- Advanz Pharma France SAS · 100% held · France · Marketing and distribution of pharmaceutical products
- Advanz Pharma Specialty Medicine Deutschland GmbH · 100% held · Germany · Marketing and distribution of pharmaceutical products
- Advanz Pharma Portugal, Unipessoal Lda · 100% held · Portugal · Marketing and distribution of pharmaceutical products
- Advanz Pharma Österreich GmbH · 100% held · Austria · Management services
- Advanz Pharma Italia S.r.l · 100% held · Italy · Marketing and distribution of pharmaceutical products
- Advanz Pharma Europe Limited · 100% held · United Kingdom · Management services
Significant events
- “On 2 December 2024, the Company signed an exclusive agreement with Bayer Aktiengesellschaft to acquire the marketing authorizations, trademarks and all distribution and other commercial know-how relating to Progynova® and Cyclo-Progynova® in the Asia-Pacific region for a consideration of £57.6 million.”
- “On 12 July 2024, the Company signed an agreement with UCB Biopharma SRL to acquire the rights of Nootropil® and Atarax® for Europe and selected countries in Latin America and Asia-Pacific for a total consideration of £131.9 million.”
- “On 7 June 2024, the Company signed a license and supply agreement with Alvotech to commercialise a biosimilar candidate for Eylea®, including an upfront payment of £12.7 million and up to £38.8 million in milestones.”
- “On 3 November 2023, the Company signed an agreement with Bayer Aktiengesellschaft to acquire the global rights to Androcur® for consideration of £22.2 million, completed on 1 February 2024.”
- “On 27 June 2024, the European Medicines Agency's (“EMA") CHMP concluded its review of Ocaliva® (obeticholic acid) and recommended the revocation of its CMA in the European Union. Subsequently, on 2 September 2024, the EC adopted CHMP's recommendation, revoking the CMA for Ocaliva® across all EU Member States and the European Economic Area ("EEA"). On 12 December 2024, the Company filed an application to appeal the Suspension Revocation at the European Court of Justice.”
- “On 15 April 2025, the Company signed an exclusive license and supply agreement for a long-acting injectable specialty medicine in selected countries throughout Europe, including the UK, as well as in Australia.”
- “On 28 May 2025, the Company signed a license and supply agreement with Alvotech to commercialize three biosimilar candidates in Europe, including an upfront payment of €50 million.”
- “On 16 June 2025, the Company signed an exclusive agreement with Bayer Aktiengesellschaft to acquire the marketing authorizations, trademarks and all distribution and other commercial know-how relating to Testoviron® (testosterone enantate) for Europe and selected markets in Latin America, the Middle East & Africa, and Asia-Pacific.”
- “On 30 June 2025, the Company signed a license and supply agreement with Alvotech to commercialize one more biosimilar candidate to Cimzia® (certolizumab pegol) in Europe, including an upfront payment of €10 million.”
- “20mcg Liothyronine tablets: On 10 October 2016, the UK Competition and Markets Authority ("CMA") commenced an investigation into ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA") in relation to the pricing of liothyronine tablets in the UK by ADVANZ PHARMA during the period 2007-2017. The CMA decision imposed various fines for the parties involved, including fines of £40.9 million for ADVANZ PHARMA companies. On 8 August 2023, CAT issued its judgment which upheld the CMA decision against the Company and the Group. On 8 May 2025, the Court of Appeal issued its judgment in which it upheld the CMA's findings against the Company and the Group. So called "follow-on claims" for reimbursement of alleged losses, related to infringement of competition law, may arise when decisions and fines are issued by the CMA. In February 2023, the Department of Health informed the Company and the Group that it is likely to pursue follow on damages claims in the event that the CMA decision is upheld on appeal.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
4 active · 46 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| TMF CORPORATE ADMINISTRATION SERVICES LIMITED | Corporate Secretary | 2022-03-16 | — | — |
| FERRY, Melvin Jeremy, Mr. | Director | 2025-02-06 | Jun 1982 | British |
| IDRIS, Amaar Fainan | Director | 2026-04-07 | May 1984 | British |
| STICKLER, Andreas | Director | 2022-01-21 | Feb 1971 | German |
Show 46 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| FARLEY, Joseph | Secretary | 1995-07-11 | 2004-12-03 |
| PATEL, Hitesh Dinubha | Secretary | 1993-03-23 | 1994-06-07 |
| PATEL, Kirti Vinubhai | Secretary | 1994-06-07 | 1995-07-11 |
| PATEL, Kirti Vinubhai | Secretary | — | 1993-03-23 |
| SULLY, Robert | Secretary | 2018-10-01 | 2022-03-16 |
| SULLY, Robert James | Secretary | 2011-07-25 | 2016-12-31 |
| VENKATESWARAN, Subramanian | Secretary | 2004-12-03 | 2011-06-24 |
| WILLIAMS, David Richard | Secretary | 2016-12-31 | 2018-10-01 |
| AHMAD, Adeel | Director | 2015-10-21 | 2022-01-31 |
| BARENFANGER, Julian Friedrich Wilhelm Maria | Director | 2012-07-23 | 2012-08-31 |
| BEIGHTON, John | Director | 2010-06-09 | 2018-11-30 |
| BROWN, Peter Michael | Director | 2003-08-01 | 2007-08-08 |
| CONNELL, Richard Andrew | Director | 2010-06-09 | 2013-02-08 |
| CONNELL, Richard Andrew | Director | 2010-06-09 | 2013-02-08 |
| DIBDEN, Lindsay George | Director | 2010-03-02 | 2012-02-27 |
| DUNCAN, Graeme Neville | Director | 2018-11-30 | 2022-01-12 |
| DUNCAN, Graeme Neville | Director | 2016-12-31 | 2018-03-08 |
| EBERSTEIN, Robert David | Director | 1992-06-18 | 1995-05-09 |
| EDWARDS, Paul Martin | Director | 2007-08-08 | 2009-12-23 |
| GOGERLY, Robert Shane | Director | — | 1992-09-25 |
| HELLAWELL, Keith, Dr. | Director | 2006-05-15 | 2009-12-23 |
| JACOB, Frances Carol | Director | 2010-03-02 | 2012-07-23 |
| KAMATH, Vikram Laxman | Director | 2012-10-23 | 2025-02-06 |
| LEONG, Justin Gary | Director | 2010-03-02 | 2012-07-23 |
| LESLIE, Alexander Francis Stewart | Director | 2012-08-31 | 2015-10-21 |
| MCALPINE, Stuart Anderson | Director | 2012-08-31 | 2014-03-21 |
| NORTON, Matthew Richard | Director | 2014-12-22 | 2015-10-21 |
| OADES, Andy Giovanni | Director | 2002-03-12 | 2003-06-24 |
| PATEL, Ajay Mafatlal | Director | 1998-01-21 | 2010-08-31 |
| PATEL, Ajit Ramanlal | Director | — | 2007-07-02 |
| PATEL, Kirti Vinubhai | Director | 2009-08-05 | 2010-05-19 |
| PATEL, Kirti Vinubhai | Director | 1992-05-01 | 2007-12-31 |
| PATEL, Mukesh Kanubhai | Director | 1992-05-01 | 1998-05-12 |
| PATEL, Rakesh Vinodrai | Director | 1998-01-21 | 2010-05-19 |
| PELTON, Kenneth Oakley | Director | 1992-06-18 | 2007-08-08 |
| RACE, Russell John | Director | 1998-07-22 | 2004-07-28 |
| RAJAGOPALAN, Supraj Ram | Director | 2012-08-31 | 2015-10-21 |
| RAMAN, Anand | Director | 2011-01-26 | 2012-10-23 |
| REARDON, Michael John | Director | 2003-06-24 | 2007-11-14 |
| SCHWALBER, Philipp Theodor | Director | 2010-03-02 | 2012-08-31 |
| STONE, Lisa | Director | 2010-03-02 | 2012-07-23 |
| SWAMY, Ram | Director | 2008-08-06 | 2010-05-31 |
| THOMPSON, Mark Laurence | Director | 2015-10-21 | 2016-12-31 |
| VAN TIGGELEN, Antonie Pieter | Director | 2013-09-25 | 2016-01-08 |
| WALTERS, David Edward | Director | 1992-06-18 | 1993-11-07 |
| WOOLLACOTT, Paul Nicholas | Director | 2007-08-08 | 2009-12-23 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Concordia Investment Holdings (Uk) Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-06-01 | Ceased 2021-11-30 |
| The Blackstone Group Inc. | Corporate entity | Shares 25–50%, Voting 25–50% | 2020-03-27 | Ceased 2021-06-01 |
| Concordia Investment Holdings (Uk) Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-08-10 | Ceased 2020-03-27 |
Filing timeline
Last 20 of 428 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-05-05 | AP01 | officers | appoint person director company with name date |
| 2026-02-17 | SH01 | capital | capital allotment shares |
| 2025-10-07 | AA | accounts | accounts with accounts type full |
| 2025-07-21 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-05-22 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2025-05-22 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2025-02-20 | AP01 | officers | appoint person director company with name date |
| 2025-02-19 | TM01 | officers | termination director company with name termination date |
| 2024-10-03 | AA | accounts | accounts with accounts type full |
| 2024-09-02 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2024-07-31 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-07-29 | CH01 | officers | change person director company with change date |
| 2024-03-14 | AA | accounts | accounts with accounts type full |
| 2023-08-02 | CH01 | officers | change person director company with change date |
| 2023-08-01 | AD01 | address | change registered office address company with date old address new address |
| 2023-07-26 | CH04 | officers | change corporate secretary company with change date |
| 2023-07-26 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-07-26 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2023-07-26 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2023-07-21 | CH01 | officers | change person director company with change date |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.